Patient & Survivor Care
News from the FDA/CDC
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
The FDA also approved ribociclib and the aromatase inhibitor letrozole packaged together for the same indication.
From the Journals
Cancer Risk: Are Pesticides the New Smoking?
A recent study evaluated cancer risks in the US population using a model that accounts for pesticide use and adjusts for various factors.
From the Journals
Is Minimal Access Nipple-Sparing Mastectomy a Safer Option?
Researchers performed a retrospective study of 1,583 patients with breast cancer who underwent conventional nipple-sparing mastectomy or minimal...
From the Journals
Should Genetic Testing Be Routine for Breast Cancer?
Researchers conducted a cross-sectional study of 729 women with newly diagnosed invasive breast cancer to assess the efficacy of universal genetic...
News from the FDA/CDC
FDA OKs Subcutaneous Atezolizumab Formulation for Multiple Cancer Indications
The drug combo was the first programmed death–ligand 1 inhibitor to gain approval for subcutaneous administration.
Conference Coverage
Osimertinib/Savolitinib Combo Shows Promise in NSCLC
Can combining two agents overcome MET-driven primary resistance in MET-aberrant, EGFR-mutated advanced NSCLC?
Conference Coverage
Treatment Options in MCL: What Are the Best Practices?
Experts on mantle cell lymphoma share findings on how best to treat patients at various ages and stages.
Conference Coverage
A Simple Blood Test May Predict Cancer Risk in T2D
Can the markers of inflammation IL-6, tumor necrosis factor alpha (TNF-alpha), and high-sensitivity C-reactive protein (hsCRP) be predictive...
Conference Coverage
Debate: Should Patients With CLL Take Breaks From Targeted Therapies?
Experts on chronic lymphocytic leukemia debated whether or not patients would benefit from discontinuing treatment at times.
Feature
KRAS Inhibitors in Pancreatic Cancer: Hope on the Horizon?
A pipeline of KRAS inhibitors targeting pancreatic cancer has emerged.
Conference Coverage
Ivonescimab: Possible New First-Line Standard in PD-L1–Positive Advanced NSCLC?
The results highlight ivonescimab’s potential to become a ‘new standard of care’ in advanced PD-L1–positive advanced NSCLC, according to an author...